Research programme: 1C metabolism pathway modulators - Raze Therapeutics

Drug Profile

Research programme: 1C metabolism pathway modulators - Raze Therapeutics

Latest Information Update: 12 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Raze Therapeutics
  • Class
  • Mechanism of Action Methylenetetrahydrofolate reductase modulators; Mitochondrial 1C metabolism modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 16 Apr 2016 Pharmaco-dynamics data from an in-vitro study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 14 Oct 2014 Early research in Haematological malignancies in USA (unspecified route)
  • 14 Oct 2014 Early research in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top